ALNEV.PA Neovacs S.A. EURONEXT 24 Feb 2026: €0.0018, 14.53M shares traded

ALNEV.PA stock closed the EURONEXT session at €0.0018 on 24 Feb 2026 after 14,525,422 shares changed hands, marking Neovacs S.A. among the market’s most active small caps today. The share rose 5.88% from the prior close of €0.0017 on heavy intraday turnover, highlighting speculative liquidity and extreme volatility in the Biotechnology sector. Market Closed on EURONEXT, and intraday flows were well above the 3-month average, signaling short-term trader interest rather than fresh fundamental news.

ALNEV.PA stock price action and volume

Neovacs (ALNEV.PA) traded between €0.0016 and €0.0018 today with a closing price of €0.0018 and a single-day change of +0.00010. Volume was 14.53M versus an average volume of 9.93M, a relative volume of 1.44, which placed the ticker on Europe’s most active lists. The intraday move occurred without a company press release, so the pattern points to retail-driven momentum and block trades rather than fresh trial updates.

ALNEV.PA stock fundamentals and valuation snapshot

Neovacs reports a market cap of €858.00 and EPS of -221.36, producing no meaningful PE multiple. Book value per share stands at 103.50 while cash per share is 2.50, giving a distorted picture because of a tiny free float; enterprise value data is negative, indicating accounting and microcap distortions. Price-to-sales is 0.00 (rounded), and the current ratio is 0.63, which flags short-term liquidity pressure. These metrics make ALNEV.PA a high-risk, speculative equity rather than a valuation-driven buy.

Technicals and trading signals for ALNEV.PA stock

Momentum indicators show extreme readings: RSI 16.07 (oversold) and ADX 78.30 (strong trend), while ROC is -43.75%, suggesting the larger move has been down over recent periods. Price averages are distorted: 50-day €0.00564 and 200-day €0.86789 reflect historical pricing anomalies. Traders should note the low cash ratio 0.11 and on‑book volume pressure (OBV negative), which combined mean swings can be sharp and short-lived.

Meyka AI grade and model forecast for ALNEV.PA stock

Meyka AI rates ALNEV.PA with a score of 62.72 out of 100 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects short-term upside scenarios but flags high downside risk; the modelled three-month target is €0.0050 and the 12-month base case is €0.0200, both model-based projections and not guarantees. For more on peer comparisons see Investing.com and the company site Neovacs.

Pipeline catalysts and risk profile for ALNEV.PA stock

Neovacs focuses on Kinoid therapeutic vaccines including IFNa Kinoid in Phase IIb for systemic lupus erythematosus and other early-stage programs; clinical readouts remain the primary upside catalyst. Key risks include tiny market cap (€858.00), extremely low liquidity, negative operating cash flow per share (-20.64), and long gaps between earnings updates (last listed earnings announcement was 2019). These factors heighten dilution and binary trial-risk for shareholders.

Trading approach and short-term strategy for ALNEV.PA stock

Given the microcap structure, active traders may use tight stop-losses and size limits; passive investors should avoid position buildup until clearer trial milestones or financing clarity. Technical traders can watch a break above €0.0050 for confirmation of a short-term reversal. Institutional coverage is minimal and analyst consensus is weak, so risk management and position sizing are essential for any ALNEV.PA exposure.

Final Thoughts

ALNEV.PA stock closed the EURONEXT session at €0.0018 on 24 Feb 2026 with 14.53M shares traded, a volume surge that reflects speculative retail interest more than new fundamental data. Meyka AI’s forecast model projects a 3-month target of €0.0050 (implied upside +177.78% versus the current price) and a 12-month base case of €0.0200 (implied upside +1,011.11%). These model projections are strictly scenario-based and not guarantees; they assume either positive clinical news or de-risking events. Our assessment: the stock is a high-volatility, high-risk microcap with meaningful upside only if clinical programs advance or financing is clarified. Traders should use strict risk controls and avoid oversized positions. Meyka AI, the AI-powered market analysis platform, flags ALNEV.PA as speculative and recommends disciplined exposure management given the company’s clinical binary catalysts and constrained liquidity.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.